[Edaily Reporter Shin Ha-yeon ] #Acryl Inc. is trading up by around 4% in early trading on news of its expanded supply of an artificial intelligence (AI) data center operations platform.
According to MP Doctor on the 29th, as of 9:23 a.m. today, Acryl Inc. is trading at 14,330 won, up 4.29% from the previous trading day. Acryl Inc. announced today that it has signed a 3.3 billion won contract with Hancom to supply “GPUBASE,” a high-end AI data center operating platform, as part of a modular data center (MDC) construction project.
This contract follows a previously signed 2.2 billion won contract for the supply of the entry-level version of GPUBASE, bringing the cumulative supply value of GPUBASE to 5.5 billion won.
The move is seen as significant because the company has secured a reference project by commercially supplying the operational software necessary for building AI data centers. As the scale of GPUs in AI data centers increases, the importance of resource allocation, network management, and power and cooling management grows; consequently, demand for platforms that provide integrated management of these elements is expected to expand.
GPUBASE is an AI data center operations platform that provides features such as optimized inter-GPU communication, integrated management of GPU, server, storage, and network resources, and real-time monitoring capabilities. The products to be supplied will be installed in a container-based AI data center equipped with NVIDIA H200 NVL GPU servers and direct liquid cooling (DLC) racks, with delivery scheduled to be completed by the third quarter of this year.
“Regulations on the 52-hour workweek should be relaxed for businesses that create new concepts or for semiconductor research and development (R&D).”KoreaInformation&Communication Technology Promotion …
Nongshim is seeking to expand its reach among young consumers through a collaboration between Welch’s—a carbonated beverage familiar to gamers, particularly those frequenting PC bangs—and the battle r…
Royvant is focusing its funding and development capabilities on IMVT-1402 (active ingredient: imeropruvate), a next-generation FcRn antibody licensed from HANALL BIOPHARMA CO.,LTD(009420). This comes …